Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06708949 · ClinicalTrials.gov registry record · Phase 2
A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)
A Phase 2 study of Renal Cell Carcinoma, Clear Cell, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
- 5
- Study locations
NCT06708949: Recruiting Phase 2 study of Renal Cell Carcinoma, Clear Cell, sponsored by M.D. Anderson Cancer Center.
NCT06708949 is a Phase 2 study of Renal Cell Carcinoma, Clear Cell that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 15 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06708949, a Phase 2 study of Renal Cell Carcinoma, Clear Cell, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a phase 2 stratified, randomized, multicenter, study investigating the efficacy of a triplet arm treating with nivolumab 480 mg every 4 weeks (Q4W), relatlimab 160 mg Q4W and ipilimumab 1 mg/kg every 8 weeks (Q8W) intravenous (IV) versus a doublet arm treating with nivolumab 480 mg Q3W and ipilimumab 1mg/kg Q3W IV in first-line advanced RCC.
Primary Outcome
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Conditions Studied
Interventions
- DRUG Ipilimumab
- DRUG Drugs Nivolumab
- DRUG BMS-986213 (Relatlimab-Nivolumab FDC)
Study Locations (5)
Texas
- University of Texas Southwestern Medical Center - Dallas
- The University of Texas M. D. Anderson Cancer Center - Houston
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
North Carolina
- Duke University Medical Center - Durham
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2025-03-20 |
| Est. Completion | 2028-12-15 |
| Phase | Phase 2 |
What NCT06708949 shows while recruiting
NCT06708949 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Renal Cell Carcinoma, Clear Cell appearing as the primary indexed condition, and to 3 interventions - of which Ipilimumab is the first listed.
NCT06708949 lists 5 locations in 4 states (Texas, Massachusetts, North Carolina).
Frequently Asked Questions
What is clinical trial NCT06708949 about?
NCT06708949 is a clinical study titled "A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)". This is a phase 2 stratified, randomized, multicenter, study investigating the efficacy of a triplet arm treating with nivolumab 480 mg every 4 weeks (Q4W), relatlimab 160 mg Q4W and ipilimumab 1 mg/kg every 8 weeks (Q8W) intravenous (IV) versus a doublet arm treating with nivolumab 480 mg Q3W and i...
What is the current status of trial NCT06708949?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2025-03-20. Estimated completion is 2028-12-15.
What conditions does trial NCT06708949 study?
This clinical trial studies the following conditions: Renal Cell Carcinoma, Clear Cell.
What interventions are being tested in trial NCT06708949?
The interventions under investigation include: Ipilimumab (DRUG), Drugs Nivolumab (DRUG), BMS-986213 (Relatlimab-Nivolumab FDC) (DRUG).
Who is sponsoring clinical trial NCT06708949?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06708949 being conducted?
This trial has 5 study locations across Massachusetts, North Carolina, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06708949's enrollment target sits among peer trials
15 1919th of 2000 higher than 60 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI